Submit an Article
Online ISSN: 1945-4589
Impact Journals, LLC. is the publisher of Aging: www.impactjournals.com.
Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.
Impact Journals is a member of the Society for Scholarly Publishing.
Learn about our FREE Post-Publication Promotion Services

Aging | Rapamycin Treatment Early in Life Reprograms Aging: Hyperfunction Theory and Clinical Practice

11-03-2022

“In conclusion, the rate of aging can be decelerated by using rapamycin during the early developmental growth phase. This has important theoretical significance but cannot be implemented in humans.”

Listen to an audio version of this press release

BUFFALO, NY- November 3, 2022 – A new research perspective was published in Aging (listed as "Aging (Albany NY)" by MEDLINE/PubMed and "Aging-US" by Web of Science) Volume 14, Issue 20, entitled, “Rapamycin treatment early in life reprograms aging: hyperfunction theory and clinical practice.”

On October 24, 2022, Mikhail Blagosklonny, M.D., Ph.D. from Roswell Park Comprehensive Cancer Center published a riveting research perspective discussing the clinical application of early-life rapamycin treatment and its ability to reprogram aging, based on the hyperfunction theory.

“Making provocative headlines, three outstanding publications demonstrated that early-life treatment with rapamycin, including treatments during developmental growth, extends lifespan in animals, confirming predictions of hyperfunction theory, which views aging as a quasi-program (an unintended continuation of developmental growth) driven in part by mTOR. 

Despite their high theoretical importance, clinical applications of two of these studies in mice, Drosophila and Daphnia cannot be implemented in humans because that would require growth retardation started at birth.

A third study demonstrated that a transient (around 20% of total lifespan in Drosophila) treatment with rapamycin early in Drosophila adult life is as effective as lifelong treatment, whereas a late-life treatment is not effective. 

However, previous studies in mice demonstrated that a transient late-life treatment is highly effective. 

Based on hyperfunction theory, this article attempts to reconcile conflicting results and suggests the optimal treatment strategy to extend human lifespan.”

DOI: https://doi.org/10.18632/aging.204354 

Corresponding Author: Mikhail V. Blagosklonny - Blagosklonny@oncotarget.com 

Keywords: senescence, gerostatics, geroscience, sirolimus, healthspan

Sign up for free Altmetric alerts about this article:  https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204354

About Aging-US:

Cancer and aging are two sides of age-related tumorigenesis.

The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.

The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)

Please visit our website at www.Aging-US.com and connect with us:

For media inquiries, please contact media@impactjournals.com.